Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 4Breast 4Tumor-Agnostic 3Other hematologic neoplasm 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Blast Crisis 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × STA 9090 × Lymphoid × Clear all
NCT00964873 2014-09-18

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Synta Pharmaceuticals Corp.

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡